Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
- CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...
- Research articles 2008-06-24
- Biotech's New Blockbusters -- Oh, Really?
- FierceBiotech's Maureen Martino has produced a "special report" that four biotech drugs poised for approval later this year could be "the next generation of biologic blockbusters" -- that is, treatments that not only pull in more than $1 billion in annual sales, but which "could offer real breakthroughs for patients"...
- Blog posts 2008-07-10
Additional Resources
- Pharma Roundup: Cephalon's Strategy, GSK: "No Big M&A," and More
- Cephalon's winning business model -- Time and time again, Cephalon buys a drug for cheap and then gives it the resources to become a success, earning big money in the process -- 2009 revenue for the company should top $2 billion. Combined with "superior drug scouting" and "hyperaggressive marketing," it's...
- Blog posts 2009-01-09
- Pharma Roundup: Pfizer Sells Experimental Drugs, Genentech Tight-Lipped on Roche, and More
- Pfizer pawns off irrelevant drugs -- Pfizer just sold rights to over 100 experimental drugs. The closeout comes on the heels of the company's autumn promise to streamline R&D; the ditched treatments focus on conditions Pfizer will no longer study, like obesity and high cholesterol. [Source: WSJ Health Blog] ...
- Blog posts 2009-01-14
- Pharma Roundup: Pfizer and the Rat, Johnson & Johnson in Europe, and More
- Pfizer's gruesome new anti-counterfeit campaign -- In the U.K., Pfizer has rolled out a new TV ad that warns consumers against the dangers of counterfeit drugs. The nauseating image of a man pulling a rat from his mouth intends to educate consumers about the dangerous substances like rat poison which...
- Blog posts 2009-01-22
- Pharma Roundup: Pfizer, Wyeth, Amgen, Bristol, and More
- Pfizer and Wyeth: how many jobs are actually being cut? -- The Health Blog provides a run-down on the various figures that are being tossed around, from 18,000 to 26,000. Their estimate with the math to back it up is 19,425 from the combined company, with at least 8,190 coming...
- Blog posts 2009-01-27
- Pharma Roundup: Glaxo's $400 Million Penalty, Cuts at AstraZeneca, and More
- GSK to lose $400 million on legal challenge -- Legal action against GlaxoSmithKline, stemming from the state of Colorado's allegations of improper marketing on nine top products, will cost $400 million, the company has announced. The charge will appear in the fourth quarter results due in February. [Source: WSJ Health...
- Blog posts 2009-01-29
- Pharma Roundup: Lilly and Prasugrel, Roche and Genentech, and More
- Prasugrel's FDA approval looks closer -- Prasugrel, the blood thinner on which Lilly is pinning so much hope, got a boost in a newly-published FDA document stating that "the Division recommends approval of prasugrel." The briefing is meant to sway the outside committee that will convene next week to advise...
- Blog posts 2009-01-30
- Biotech Investors Await Talecris Biotherapeutics' Imminent IPO
- Abbi Adest submits: Talecris Biotherapeutics TLCR plans to go public this week. The biotech company is a maker of plasma-derived protein therapies, formerly for Bayer. According to FierceBiotech, the company had originally planned to go public back in 2007, before the market meltdown pushed share prices down. But...
- External links 2009-09-29
- The biotech-pharma partnership recipe
- At no point in the history of drug research have biotech companies and Big Pharma been so closely aligned. Pharma companies have been turning more and more often to biotechs for the kind of cutting-edge technology they need to replenish pipelines. Biotechs routinely build partnership pacts with pharma into their...
- News items 2009-10-06
- Europe's Top 5 Biotech Hotspots
- For decades European countries have been among the most innovative on the planet when it comes to drug development. So our siste publication FierceBiotech is taking a look at the development scene solely in Europe to see which countries have hatched the best programs to support drug discovery and innovation....
- News items 2009-10-07
- Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
- Pfizer CEO seeks big acquisition — In a much-discussed comment to the Financial Times, Pfizer's CEO Jeff Kindler revealed his aspirations for revenue-boosting deals, large and small. As the Health Blog points out, the takeaway here is Kindler's apparent willingness to pursue old-fashioned big acquisitions, at a time when most...
- News items 2009-08-07
- Inovio shares jump (again) on vax research pact
- Shares of Inovio Biomedical jumped again on Monday after the San Diego-based biotech company announced a pact with the NIH Vaccine Research Center to explore new universal influenza jabs and speed development of swine flu vaccines. Inovio is one of a relative handful of small biotech companies that have been buoyed...
- News items 2009-08-11
- On the Radar: Five biotech companies to watch
- Partnering deals, regulatory actions and fresh clinical trial data make up a big part of what we cover here at FierceBiotech . So we decided to start asking some prominent market analysts to give us an inside look at what they're watching for on the near horizon. Today...
- News items 2009-09-02
- << Previous
- page 1 of 1
- Next >>
Presented by American Express